Twist Bioscience (TWST) Receivables - Net (2018 - 2026)

Twist Bioscience (TWST) has 9 years of Receivables - Net data on file, last reported at $64.2 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $64.2 million, up 28.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.2 million (up 28.44% YoY), and the FY2025 annual result was $57.0 million, up 63.36% from the prior year.
• Receivables - Net advanced to $64.2 million in Q1 2026 per TWST's latest filing, from $50.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $64.2 million in Q1 2026 and troughed at $32.0 million in Q2 2024.
• A 5-year average of $43.8 million and a median of $42.6 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net dropped 25.31% in 2024, then soared 63.36% in 2025.
• A 5-year view of Receivables - Net shows it stood at $44.4 million in 2022, then fell by 20.44% to $35.4 million in 2023, then advanced by 11.2% to $39.3 million in 2024, then increased by 27.34% to $50.1 million in 2025, then grew by 28.15% to $64.2 million in 2026.
• Business Quant data shows TWST's Receivables - Net at $64.2 million in Q1 2026, $50.1 million in Q4 2025, and $57.0 million in Q3 2025.